Hims & Hers Health Inc. shares slid over 2.8% on Tuesday and continued declining after-hours trading after Eli Lilly ...

Historically, optic nerve involvement has been excluded from MS diagnostic criteria, but its inclusion in the new iteration ...

Eli Lilly will be presenting data from studies on multiple GLP-1 drugs later this month. Eli Lilly (NYSE: LLY) stock hasn't ...

Looking at licensing deals struck in the past 10 years, Jefferies found that many Big Pharmas do not ultimately follow ...

Since its founding in 2014, a16z Bio+ Health has raised four funds of nearly $3 billion each, including a $1.5 billion fund ...

Health-care companies rose amid sales growth optimism. Drug-store chain CVS Health said it has seen complaints of strong push back from patients on its pharmacy-benefit manager's move to favor Novo ...

"Under the circumstances—including the lack of evidence regarding harm that Nike will suffer, the brevity of the stay, and ...

By Bhanvi Satija and Christy Santhosh (Reuters) -Talks with the Trump administration about lowering U.S. drug prices have so ...

BioSpace did a deep dive into executive pay, examining the highest compensation packages, pay ratios and golden ...

FacebookTweetPin Energy, healthcare, and chip stocks are carrying the market today. The S&P 500 Energy sector is up 2.16%, ...

The Scorpion Therapeutics spinoff sold rights for two EGFR inhibitors to Pierre Fabre Laboratories and is hoping to become a clinical-stage firm by 2026.

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...